Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Binimetinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 59,178Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pfizer's BRAFTOVI + MEKTOVI Shows Long-Term Response In NSCLC
    Pfizer's BRAFTOVI + MEKTOVI Shows Long-Term Response In NSCLC

    14 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240913128678/en

    BUSINESSWIRE
    14 Sep 2024
    Share Share
    EMA validates Pierre Fabre's MAA for BRAFTOVI
    EMA validates Pierre Fabre's MAA for BRAFTOVI

    02 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/european-medicines-agency-validates-pierre-fabre-laboratories-marketing-authorisation-application-for-combination-braftovi-encorafenib-and-mektovi-binimetinib-for-patients-with-brafv600-mutant-advanced-non-small-cell-lung-c-301975614.html

    PR NEWSWIRE
    02 Nov 2023
    Share Share
    US clears Pfizer's Braftovi, Mektovi combo for use in lung cancer
    US clears Pfizer's Braftovi, Mektovi combo for use in lung cancer

    13 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231011089993/en

    BUSINESSWIRE
    13 Oct 2023
    Share Share
    Encorafenib/Binimetinib Combo Highlights Novel Therapies for BRAF V600+ NSCLC
    Encorafenib/Binimetinib Combo Highlights Novel Therapies for BRAF V600+ NSCLC

    31 Aug 2023

    // Kyle Doherty ONCLIVE

    https://www.onclive.com/view/encorafenib-binimetinib-combo-highlights-novel-therapies-for-braf-v600-nsclc

    Kyle Doherty ONCLIVE
    31 Aug 2023
    Share Share
    Enforcement Report - Week of April 19, 2023
    Enforcement Report - Week of April 19, 2023

    19 Apr 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-19-2023-50304.pdf

    FDA
    19 Apr 2023
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Mektovi (Binimetinib)
    FDA Confirms Paragraph IV Patent Litigation for Mektovi (Binimetinib)

    24 Aug 2022

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-mektovi-binimetinib-1661948789.pdf

    FDA
    24 Aug 2022
    Share Share